Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown

Merck’s oncology drug Keytruda will outpace all Rx brands by global sales in 2028, as Roche rides its biologics stable to become the frontrunner among pharma companies, according to a five-year World Preview recently published by Evaluate.